AAGH IconAAGH Text
Founded December 14, 2018

Brilliant Healthcare LtdPartnership

AAGH partners with Brilliant Healthcare Ltd, a Hong Kong-based company committed to providing excellent healthcare services with innovative technology and personalized health management systems.

Room 405, 4/F, Nan Fung Commercial Center

19 Lam Lok Street, Kowloon Bay, Hong Kong

About Brilliant Healthcare Ltd

A pioneering company in regenerative medicine with revolutionary patented technology for wound healing and anti-aging treatments.

Leadership & Innovation

Founded by Dr. Guo Aihua, a double doctor of plastic surgery and transplantation immunology. Dr. Guo developed the patented mini skin technology, which is the only in vitro synthetic and transplantable active organ containing stem cell germinal layer in the field of international regenerative medicine.

During the 2020 pandemic, Brilliant Healthcare was actively involved in introducing and distributing COVID-related products in Hong Kong and countries across Europe, South America, and North America, helping complete registration through local partnerships.

Joint Venture Agreement

On December 7th, 2020, America Great Health (California Corporation) entered into a cooperation agreement with Brilliant Healthcare Limited to establish a joint venture in China.

AAGH invests USD $4.2 million for 60% equity
Brilliant contributes USD $29.8 million in patented technology for 40% equity
Patent Technology

Mini Skin Structure Patent

Revolutionary patented technology that transforms wound healing from passive to active repair mechanisms using stem cell technology.

Patent Details

Patent Name:

The preparation and clinical application for a Mini skin structure

Patent Number:

ZL201010188002.X

Patentee & Inventor:

Dr. Aihua Guo

Patent Value:

USD $50-59 million (December 2020)

Technology Overview

The invention involves a mini skin structure integrated in vitro by epidermal cells and dermal cells, its preparation, and clinical application in regenerative medicine and the aesthetic industry.

This technology completely changes wound healing from traditional passive healing to an active healing mechanism where stem cells differentiate into fibroblast and epidermal cells, dominating the healing process.

Technology Advantages

Only 3D skin structure with active stem cells and different cell types
No need for collagen scaffolds or additional supporting biomaterials
Only existing skin substitute containing self-generated basement membrane
Stem cells act as cell bank for stable tissue regeneration
Can be cryopreserved and transported easily for shelf-ready products
Free of antigens, suitable for allogeneic transplantation
Relatively inexpensive manufacturing with easy mass production scaling
Applications extend to pharmaceutical testing and disease modeling

Clinical Applications

Three major therapeutic applications targeting large and growing markets with proven technology readiness.

Wound Healing

Treatment of patients with burns, open wounds, and diabetic ulcers using active stem cell repair mechanisms instead of traditional passive healing methods.

Facial Anti-Aging Treatments

Stem cell-enriched technology that produces stronger collagen and cytokines formation, providing robust tissue repair compared to single fibroblast injections.

Hair Regeneration

In vivo hair follicle production using dermal sheath cells and epidermal cells, capable of producing human hair in animal models.

Market Valuation

The three main applications have been independently valued at CNY 387 million, equivalent to approximately USD $59 million at current exchange rates.

Technology for wound healing and anti-aging applications is considered fully developed, while hair treatment requires further optimization of treatment conditions and carrier ratios.

Key Facts & Achievements

Founded December 14, 2018 in Hong Kong
Located at Kowloon Bay, Hong Kong
Active COVID-19 product distribution during 2020 pandemic
Joint venture with America Great Health (California Corporation)
USD $4.2 million AAGH investment for 60% equity ownership
Brilliant Healthcare contributes USD $29.8 million in patented technology for 40% equity
Patent valued between USD $50-59 million as of December 2020
Three applications independently valued at CNY 387 million (USD $59 million)

Future Applications

Beyond therapeutic applications, this technology is expected to be used for basic clinical research, pharmaceutical drug screening, cosmetics testing, and disease modeling globally.

The technology holds several advantages due to its innovativeness, uniqueness, practicability, versatility, immuno-privilege, and authenticity.